MDNA Life Sciences acquires Mitomic Technology and product pipeline.
Sophisticated new prostate cancer tests are coming to market that might supplement the unreliable P.S.A. test, potentially saving tens of thousands of men each year from unnecessary biopsies, operations and radiation treatments.
Read the full article on the New York Times.
In the world of early disease detection, Mitomics Inc. is pioneering the next generation of molecular testing. The Thunder Bay-based company is charting new territory with an innovative approach to the screening and diagnosis of cancer by using mitochondrial DNA (mtDNA) based biomarkers instead of traditional nuclear DNA-based biomarkers.
Read the full article on the Biotechnolgy Focus website.
Titanic’s unknown child: The critical role of the mitochondrial DNA coding region in a re-identification effort.
Read the full report on the ScienceDirect website.
ARUP Labs plans to begin offering Decode’s prostate cancer-risk test to clients nationwide in the fall, the companies said.